首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Journal of clinical urology

缩写:

ISSN:2051-4158

e-ISSN:2051-4166

IF/分区:0.5/Q4

文章目录 更多期刊信息

共收录本刊相关文章索引17
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Keval M Patel,Vincent J Gnanapragasam Keval M Patel
Since Partin introduced the analysis of prostate-specific antigen, clinical T-stage and Gleason scores to estimate the risk of progression in men with localised prostate cancer, our understanding of factors that modify this risk has changed...
Hugh Harvey,Nandita M deSouza Hugh Harvey
Ultrasound and magnetic resonance imaging (MRI) are key imaging modalities in prostate cancer diagnosis. MRI offers a range of intrinsic contrast mechanisms (T2, diffusion-weighted imaging (DWI), MR spectroscopy (MRS)) and extrinsic contras...
Niels Asger Jakobsen,Freddie Charles Hamdy,Richard John Bryant Niels Asger Jakobsen
Prostate-specific antigen (PSA) is widely used as a biomarker in the detection of prostate cancer and for decision making regarding treatment options, response to therapy, and clinical follow-up. Despite its widespread use, it is well recog...
Caroline Graham,John M Reynard,Benjamin W Turney Caroline Graham
Objective: The objective of this article is to assess the readability of leaflets about urological procedures provided by the British Association of Urological Surgeons (BAUS) to evaluate their suitability for providing i...
Friedrich-Carl von Rundstedt,Douglas A Mata,Steven Shen et al. Friedrich-Carl von Rundstedt et al.
Purpose: Biopsy of the prostatic urethra is an integral part of clinical staging in patients prior to radical cystoprostatectomy (RC) and urinary diversion. We examined whether preoperative transurethral resection (TUR) b...
J H Seth,C Dowson,M S Khan et al. J H Seth et al.
Background: Botulinum toxin-A (BoNT/A) is now established second-line management for refractory overactive bladder (OAB) and recognised in many incontinence guidelines and pathways. For those with neurogenic detrusor over...